Cagrilintide

Cagrilintide is a synthetic long-acting analog of amylin, the 37-amino-acid peptide hormone produced by pancreatic β-cells. Its development report describes a stable, lipidated analog selected after structure-activity work that addressed amylin’s strong tendency to form amyloid fibrils. Preclinical research on the cagrilintide peptide has examined amylin receptors, which pair the calcitonin receptor with RAMP1, 2 or 3, along with hindbrain neuronal activation and food intake in RAMP knockout mice. Research Market supplies cagrilintide with purity and identity data for each lot reported on its certificate of analysis. It is sold strictly for laboratory research use.

Chemical structure and identification

• Molecular formula: C₁₉₄H₃₁₂N₅₄O₅₉S₂
• Molecular weight: 4409 g/mol
• CAS number: 1415456-99-3
• PubChem CID: 171397054
• Amino acid sequence: N-(19-carboxynonadecanoyl)-γGlu-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH₂ (37 residues, disulfide bridge between the two cysteines)
• Synonyms: NN0174-0833
• Form: Lyophilized powder
• Analytical methods: RP-HPLC for purity and mass spectrometry for identity, reported on the batch certificate of analysis

Research applications

• Analog development: The development report describes cagrilintide as a stable, lipidated long-acting amylin analogue and presents some of the structure-activity work that led to its selection [1]
• Amylin receptor pharmacology: Amylin receptors are multisubunit G protein-coupled receptors formed by a core receptor protein and receptor activity-modifying proteins; reviewed rodent and human work places amylin’s main action in the circumventricular organs [2]
• AMY1 and AMY3 receptors: In high-fat-fed RAMP1/3 knockout mice, the effects of cagrilintide on body weight and on cFos activation in the area postrema were reduced compared with wild-type littermates, linking its action to AMY1 and AMY3 receptors [3]
• Brain circuitry: Reviewed amylin signaling from the area postrema to the nucleus of the solitary tract and lateral parabrachial nucleus, and its action on arcuate POMC and NPY neurons [4]

Reference citations

1. Kruse T. et al. (2021). Development of cagrilintide, a long-acting amylin analogue. J Med Chem, 64(15):11183–11194. PMID 34288673 · DOI
2. Hay D.L. et al. (2015). Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev, 67(3):564–600. PMID 26071095 · DOI
3. Carvas A.O. et al. (2025). Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine, 118:105836. PMID 40609154 · DOI
4. Boccia L. et al. (2020). Amylin brain circuitry. Peptides, 132:170366. PMID 32634450 · DOI

Compound data from PubChem CID 171397054. Literature summaries describe published preclinical research and are not claims about this product’s effects in humans or animals.